[High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16)(p13q22)].
A 20-year-old Japanese woman was diagnosed as having acute myeloid leukemia with inv(16)(p13 q22). She achieved complete remission (CR) after treatment with a standard dose of cytarabine(ara-C) and idarubicin. She received high dose ara-C and etoposide for the 2nd consolidation chemotherapy. On the 5th fraction of high dose ara-C, her heart rate dropped to 52/minute and returned to 72/minute after the cessation of ara-C. After achieving informed consent, we gave her another course of high dose ara-C, which once again resulted in a decreased heart rate. This suggests that the administration of high dose ara-C could cause bradycardia.
Kumagawa
Midori
M
Blood Transfusion Unit of Fukuoka University Hospital, First Department of Internal Medicine, School of Medicine, Fukuoka University.
Suzuki
Keiko
K
Nagano
Mitsuyuki
M
Takamatsu
Yasushi
Y
Suzumiya
Junji
J
Tamura
Kazuo
K
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001919:Bradycardia / Q000139:chemically induced*; D007446:Chromosome Inversion; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects*; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics*; D012074:Remission Induction
D003561:Cytarabine; D005047:Etoposide; D015255:Idarubicin